Switch theme
Sign up to access all valuation multiples
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
1931
77.3K+
LTM Revenue $46.4B
LTM EBITDA $22.8B
$315B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Novo Nordisk has a last 12-month revenue of $46.4B and a last 12-month EBITDA of $22.8B.
In the most recent fiscal year, Novo Nordisk achieved revenue of $43.7B and an EBITDA of $20.7B.
Novo Nordisk expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Novo Nordisk valuation multiples based on analyst estimates| LTM | NTM | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | $46.4B | XXX | XXX | XXX | XXX |
| Gross Profit | $39.1B | XXX | XXX | XXX | XXX |
| Gross Margin | 84% | XXX | XXX | XXX | XXX |
| EBITDA | $22.8B | XXX | XXX | XXX | XXX |
| EBITDA Margin | 49% | XXX | XXX | XXX | XXX |
| EBIT | $20.7B | XXX | XXX | XXX | XXX |
| EBIT Margin | 45% | XXX | XXX | XXX | XXX |
| Net Profit | $16.2B | XXX | XXX | XXX | XXX |
| Net Margin | 35% | XXX | XXX | XXX | XXX |
| Net Debt | $12.1B | XXX | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Novo Nordisk's stock price is DKK 454 (or $68).
Novo Nordisk has current market cap of DKK 2.02T (or $304B), and EV of DKK 2.09T (or $315B).
See Novo Nordisk trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $315B | $304B | XXX | XXX | XXX | XXX | $3.64 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Novo Nordisk has market cap of $304B and EV of $315B.
Novo Nordisk's trades at 6.8x EV/LTM Revenue multiple, and 13.8x EV/LTM EBITDA.
Equity research analysts estimate Novo Nordisk's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Novo Nordisk has a P/E ratio of 18.8x.
See valuation multiples for Novo Nordisk and 10K+ public comps| LTM | NTM | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Market cap (current) | $304B | XXX | XXX | XXX | XXX |
| EV (current) | $315B | XXX | XXX | XXX | XXX |
| EV/Revenue | 6.8x | XXX | XXX | XXX | XXX |
| EV/EBITDA | 13.8x | XXX | XXX | XXX | XXX |
| EV/EBIT | 15.2x | XXX | XXX | XXX | XXX |
| EV/Gross Profit | 8.1x | XXX | XXX | XXX | XXX |
| P/E | 18.8x | XXX | XXX | XXX | XXX |
| EV/FCF | 111.6x | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNovo Nordisk's last 12 month revenue growth is 15%
Novo Nordisk's revenue per employee for the last 12 months averaged $0.6M, while opex per employee averaged $0.2M for the same period.
Novo Nordisk's rule of 40 is 64% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Novo Nordisk's rule of X is 87% (another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Novo Nordisk and other 10K+ public comps| LTM | NTM | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 49% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | XXX | XXX | XXX |
| Rule of 40 | 64% | XXX | XXX | XXX | XXX |
| Bessemer Rule of X | 87% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.6M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 21% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 17% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 40% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Novo Nordisk acquired XXX companies to date.
Last acquisition by Novo Nordisk was XXXXXXXX, XXXXX XXXXX XXXXXX . Novo Nordisk acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Novo Nordisk founded? | Novo Nordisk was founded in 1931. |
| Where is Novo Nordisk headquartered? | Novo Nordisk is headquartered in Denmark. |
| How many employees does Novo Nordisk have? | As of today, Novo Nordisk has 77.3K+ employees. |
| Who is the CEO of Novo Nordisk? | Novo Nordisk's CEO is Mr. Lars Fruergaard Jorgensen. |
| Is Novo Nordisk publicy listed? | Yes, Novo Nordisk is a public company listed on CSE. |
| What is the stock symbol of Novo Nordisk? | Novo Nordisk trades under NOVO B ticker. |
| When did Novo Nordisk go public? | Novo Nordisk went public in 1993. |
| Who are competitors of Novo Nordisk? | Similar companies to Novo Nordisk include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Novo Nordisk? | Novo Nordisk's current market cap is $304B |
| What is the current revenue of Novo Nordisk? | Novo Nordisk's last 12 months revenue is $46.4B. |
| What is the current revenue growth of Novo Nordisk? | Novo Nordisk revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of Novo Nordisk? | Current revenue multiple of Novo Nordisk is 6.8x. |
| Is Novo Nordisk profitable? | Yes, Novo Nordisk is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Novo Nordisk? | Novo Nordisk's last 12 months EBITDA is $22.8B. |
| What is Novo Nordisk's EBITDA margin? | Novo Nordisk's last 12 months EBITDA margin is 49%. |
| What is the current EV/EBITDA multiple of Novo Nordisk? | Current EBITDA multiple of Novo Nordisk is 13.8x. |
| What is the current FCF of Novo Nordisk? | Novo Nordisk's last 12 months FCF is $2.8B. |
| What is Novo Nordisk's FCF margin? | Novo Nordisk's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of Novo Nordisk? | Current FCF multiple of Novo Nordisk is 111.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
